Global Human Microbiome Industry
Global Human Microbiome Market to Reach US$964. 5 Million by the Year 2027. Amid the COVID-19 crisis, the global market for Human Microbiome estimated at US$391 Million in the year 2020, is projected to reach a revised size of US$964.
New York, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Human Microbiome Industry" - https://www.reportlinker.com/p05956987/?utm_source=GNW
5 Million by 2027, growing at a CAGR of 13.8% over the analysis period 2020-2027.Acute Diarrhea, one of the segments analyzed in the report, is projected to grow at a 14.9% CAGR to reach US$527 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Obesity segment is readjusted to a revised 12.6% CAGR for the next 7-year period. This segment currently accounts for a 4.7% share of the global Human Microbiome market.
The U.S. Accounts for Over 29.6% of Global Market Size in 2020, While China is Forecast to Grow at a 13.2% CAGR for the Period of 2020-2027
The Human Microbiome market in the U.S. is estimated at US$115.6 Million in the year 2020. The country currently accounts for a 29.56% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$167.2 Million in the year 2027 trailing a CAGR of 13.2% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.2% and 11.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR while Rest of European market (as defined in the study) will reach US$167.2 Million by the year 2027.
Diabetes Segment Corners a 3.8% Share in 2020
In the global Diabetes segment, USA, Canada, Japan, China and Europe will drive the 13.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$12 Million in the year 2020 will reach a projected size of US$29.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$114.2 Million by the year 2027.We bring years of research experience to this 8th edition of our report. The 247-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
*Competitors identified in this market include, among others, *
· DowDuPont, Inc.
· Enterome SA
· Merck & Co., Inc.
· Metabiomics Corporation
· Microbiome Therapeutics, LLC.
· Osel, Inc.
· Second Genome
· Vedanta Biosciences, Inc.
· ViThera Pharmaceuticals, Inc.
· Yakult Honsha Co., Ltd.
Read the full report: https://www.reportlinker.com/p05956987/?utm_source=GNW
*I. INTRODUCTION, METHODOLOGY & REPORT SCOPE*
*II. EXECUTIVE SUMMARY*
1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Human Microbiome Competitor Market Share Scenario Worldwide
(in %): 2018E
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Human Microbiome
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 2: World Historic Review for Human Microbiome by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017
Table 3: World 15-Year Perspective for Human Microbiome by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2018 & 2027
Table 4: World Current & Future Analysis for Acute Diarrhea by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 5: World Historic Review for Acute Diarrhea by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017
Table 6: World 15-Year Perspective for Acute Diarrhea by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027
Table 7: World Current & Future Analysis for Obesity by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 8: World Historic Review for Obesity by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 9: World 15-Year Perspective for Obesity by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027
Table 10: World Current & Future Analysis for Diabetes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 11: World Historic Review for Diabetes by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017
Table 12: World 15-Year Perspective for Diabetes by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027
Table 13: World Current & Future Analysis for Autoimmune
Disorders by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2027
Table 14: World Historic Review for Autoimmune Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017
Table 15: World 15-Year Perspective for Autoimmune Disorders by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027
Table 16: World Current & Future Analysis for Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 17: World Historic Review for Cancer by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 18: World 15-Year Perspective for Cancer by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027
Table 19: World Current & Future Analysis for Mental Disorders
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 20: World Historic Review for Mental Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017
Table 21: World 15-Year Perspective for Mental Disorders by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027
Table 22: World Current & Future Analysis for Other Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 23: World Historic Review for Other Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017
Table 24: World 15-Year Perspective for Other Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027
Table 25: World Current & Future Analysis for Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 26: World Historic Review for Therapeutics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017
Table 27: World 15-Year Perspective for Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027
Table 28: World Current & Future Analysis for Diagnostics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 29: World Historic Review for Diagnostics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017
Table 30: World 15-Year Perspective for Diagnostics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027
Table 31: World Current & Future Analysis for Probiotics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 32: World Historic Review for Probiotics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017
Table 33: World 15-Year Perspective for Probiotics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027
Table 34: World Current & Future Analysis for Prebiotics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 35: World Historic Review for Prebiotics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017
Table 36: World 15-Year Perspective for Prebiotics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027
Table 37: World Current & Future Analysis for Foods by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 38: World Historic Review for Foods by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 39: World 15-Year Perspective for Foods by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027
Table 40: World Current & Future Analysis for Medical Foods by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 41: World Historic Review for Medical Foods by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017
Table 42: World 15-Year Perspective for Medical Foods by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027
Table 43: World Current & Future Analysis for Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 44: World Historic Review for Drugs by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 45: World 15-Year Perspective for Drugs by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027
Table 46: World Current & Future Analysis for Other Product
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027
Table 47: World Historic Review for Other Product Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017
Table 48: World 15-Year Perspective for Other Product Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027
*III. MARKET ANALYSIS*
GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Human Microbiome Market Share (in %) by Company: 2018 & 2027
Market Analytics
Table 49: USA Current & Future Analysis for Human Microbiome by
Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2018 through 2027
Table 50: USA Historic Review for Human Microbiome by Disease
Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune
Disorders, Cancer, Mental Disorders and Other Diseases Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 51: USA 15-Year Perspective for Human Microbiome by
Disease Indication - Percentage Breakdown of Value Sales for
Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders,
Cancer, Mental Disorders and Other Diseases for the Years 2012,
2018 & 2027
Table 52: USA Current & Future Analysis for Human Microbiome by
Application - Therapeutics and Diagnostics - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027
Table 53: USA Historic Review for Human Microbiome by
Application - Therapeutics and Diagnostics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 54: USA 15-Year Perspective for Human Microbiome by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
Table 55: USA Current & Future Analysis for Human Microbiome by
Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types - Independent Analysis of Annual
Sales in US$ Million for the Years 2018 through 2027
Table 56: USA Historic Review for Human Microbiome by Product
Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and
Other Product Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2017
Table 57: USA 15-Year Perspective for Human Microbiome by
Product Type - Percentage Breakdown of Value Sales for
Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other
Product Types for the Years 2012, 2018 & 2027
CANADA
Table 58: Canada Current & Future Analysis for Human Microbiome
by Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2018 through 2027
Table 59: Canada Historic Review for Human Microbiome by
Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 60: Canada 15-Year Perspective for Human Microbiome by
Disease Indication - Percentage Breakdown of Value Sales for
Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders,
Cancer, Mental Disorders and Other Diseases for the Years 2012,
2018 & 2027
Table 61: Canada Current & Future Analysis for Human Microbiome
by Application - Therapeutics and Diagnostics - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027
Table 62: Canada Historic Review for Human Microbiome by
Application - Therapeutics and Diagnostics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 63: Canada 15-Year Perspective for Human Microbiome by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
Table 64: Canada Current & Future Analysis for Human Microbiome
by Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types - Independent Analysis of Annual
Sales in US$ Million for the Years 2018 through 2027
Table 65: Canada Historic Review for Human Microbiome by
Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017
Table 66: Canada 15-Year Perspective for Human Microbiome by
Product Type - Percentage Breakdown of Value Sales for
Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other
Product Types for the Years 2012, 2018 & 2027
JAPAN
Table 67: Japan Current & Future Analysis for Human Microbiome
by Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2018 through 2027
Table 68: Japan Historic Review for Human Microbiome by Disease
Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune
Disorders, Cancer, Mental Disorders and Other Diseases Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 69: Japan 15-Year Perspective for Human Microbiome by
Disease Indication - Percentage Breakdown of Value Sales for
Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders,
Cancer, Mental Disorders and Other Diseases for the Years 2012,
2018 & 2027
Table 70: Japan Current & Future Analysis for Human Microbiome
by Application - Therapeutics and Diagnostics - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027
Table 71: Japan Historic Review for Human Microbiome by
Application - Therapeutics and Diagnostics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 72: Japan 15-Year Perspective for Human Microbiome by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
Table 73: Japan Current & Future Analysis for Human Microbiome
by Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types - Independent Analysis of Annual
Sales in US$ Million for the Years 2018 through 2027
Table 74: Japan Historic Review for Human Microbiome by Product
Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and
Other Product Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2017
Table 75: Japan 15-Year Perspective for Human Microbiome by
Product Type - Percentage Breakdown of Value Sales for
Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other
Product Types for the Years 2012, 2018 & 2027
CHINA
Table 76: China Current & Future Analysis for Human Microbiome
by Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2018 through 2027
Table 77: China Historic Review for Human Microbiome by Disease
Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune
Disorders, Cancer, Mental Disorders and Other Diseases Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 78: China 15-Year Perspective for Human Microbiome by
Disease Indication - Percentage Breakdown of Value Sales for
Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders,
Cancer, Mental Disorders and Other Diseases for the Years 2012,
2018 & 2027
Table 79: China Current & Future Analysis for Human Microbiome
by Application - Therapeutics and Diagnostics - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027
Table 80: China Historic Review for Human Microbiome by
Application - Therapeutics and Diagnostics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 81: China 15-Year Perspective for Human Microbiome by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
Table 82: China Current & Future Analysis for Human Microbiome
by Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types - Independent Analysis of Annual
Sales in US$ Million for the Years 2018 through 2027
Table 83: China Historic Review for Human Microbiome by Product
Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and
Other Product Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2017
Table 84: China 15-Year Perspective for Human Microbiome by
Product Type - Percentage Breakdown of Value Sales for
Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other
Product Types for the Years 2012, 2018 & 2027
EUROPE
Market Facts & Figures
European Human Microbiome Market: Competitor Market Share
Scenario (in %) for 2018 & 2027
Market Analytics
Table 85: Europe Current & Future Analysis for Human Microbiome
by Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2018 through 2027
Table 86: Europe Historic Review for Human Microbiome by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 87: Europe 15-Year Perspective for Human Microbiome by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2018 & 2027
Table 88: Europe Current & Future Analysis for Human Microbiome
by Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2018 through 2027
Table 89: Europe Historic Review for Human Microbiome by
Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 90: Europe 15-Year Perspective for Human Microbiome by
Disease Indication - Percentage Breakdown of Value Sales for
Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders,
Cancer, Mental Disorders and Other Diseases for the Years 2012,
2018 & 2027
Table 91: Europe Current & Future Analysis for Human Microbiome
by Application - Therapeutics and Diagnostics - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027
Table 92: Europe Historic Review for Human Microbiome by
Application - Therapeutics and Diagnostics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 93: Europe 15-Year Perspective for Human Microbiome by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
Table 94: Europe Current & Future Analysis for Human Microbiome
by Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types - Independent Analysis of Annual
Sales in US$ Million for the Years 2018 through 2027
Table 95: Europe Historic Review for Human Microbiome by
Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017
Table 96: Europe 15-Year Perspective for Human Microbiome by
Product Type - Percentage Breakdown of Value Sales for
Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other
Product Types for the Years 2012, 2018 & 2027
FRANCE
Table 97: France Current & Future Analysis for Human Microbiome
by Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2018 through 2027
Table 98: France Historic Review for Human Microbiome by
Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 99: France 15-Year Perspective for Human Microbiome by
Disease Indication - Percentage Breakdown of Value Sales for
Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders,
Cancer, Mental Disorders and Other Diseases for the Years 2012,
2018 & 2027
Table 100: France Current & Future Analysis for Human
Microbiome by Application - Therapeutics and Diagnostics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027
Table 101: France Historic Review for Human Microbiome by
Application - Therapeutics and Diagnostics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 102: France 15-Year Perspective for Human Microbiome by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
Table 103: France Current & Future Analysis for Human
Microbiome by Product Type - Probiotics, Prebiotics, Foods,
Medical Foods, Drugs and Other Product Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027
Table 104: France Historic Review for Human Microbiome by
Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017
Table 105: France 15-Year Perspective for Human Microbiome by
Product Type - Percentage Breakdown of Value Sales for
Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other
Product Types for the Years 2012, 2018 & 2027
GERMANY
Table 106: Germany Current & Future Analysis for Human
Microbiome by Disease Indication - Acute Diarrhea, Obesity,
Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and
Other Diseases - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027
Table 107: Germany Historic Review for Human Microbiome by
Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 108: Germany 15-Year Perspective for Human Microbiome by
Disease Indication - Percentage Breakdown of Value Sales for
Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders,
Cancer, Mental Disorders and Other Diseases for the Years 2012,
2018 & 2027
Table 109: Germany Current & Future Analysis for Human
Microbiome by Application - Therapeutics and Diagnostics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027
Table 110: Germany Historic Review for Human Microbiome by
Application - Therapeutics and Diagnostics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 111: Germany 15-Year Perspective for Human Microbiome by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
Table 112: Germany Current & Future Analysis for Human
Microbiome by Product Type - Probiotics, Prebiotics, Foods,
Medical Foods, Drugs and Other Product Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027
Table 113: Germany Historic Review for Human Microbiome by
Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017
Table 114: Germany 15-Year Perspective for Human Microbiome by
Product Type - Percentage Breakdown of Value Sales for
Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other
Product Types for the Years 2012, 2018 & 2027
ITALY
Table 115: Italy Current & Future Analysis for Human Microbiome
by Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2018 through 2027
Table 116: Italy Historic Review for Human Microbiome by
Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 117: Italy 15-Year Perspective for Human Microbiome by
Disease Indication - Percentage Breakdown of Value Sales for
Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders,
Cancer, Mental Disorders and Other Diseases for the Years 2012,
2018 & 2027
Table 118: Italy Current & Future Analysis for Human Microbiome
by Application - Therapeutics and Diagnostics - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027
Table 119: Italy Historic Review for Human Microbiome by
Application - Therapeutics and Diagnostics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 120: Italy 15-Year Perspective for Human Microbiome by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
Table 121: Italy Current & Future Analysis for Human Microbiome
by Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types - Independent Analysis of Annual
Sales in US$ Million for the Years 2018 through 2027
Table 122: Italy Historic Review for Human Microbiome by
Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017
Table 123: Italy 15-Year Perspective for Human Microbiome by
Product Type - Percentage Breakdown of Value Sales for
Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other
Product Types for the Years 2012, 2018 & 2027
UNITED KINGDOM
Table 124: UK Current & Future Analysis for Human Microbiome by
Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2018 through 2027
Table 125: UK Historic Review for Human Microbiome by Disease
Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune
Disorders, Cancer, Mental Disorders and Other Diseases Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 126: UK 15-Year Perspective for Human Microbiome by
Disease Indication - Percentage Breakdown of Value Sales for
Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders,
Cancer, Mental Disorders and Other Diseases for the Years 2012,
2018 & 2027
Table 127: UK Current & Future Analysis for Human Microbiome by
Application - Therapeutics and Diagnostics - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027
Table 128: UK Historic Review for Human Microbiome by
Application - Therapeutics and Diagnostics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017
Table 129: UK 15-Year Perspective for Human Microbiome by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
Table 130: UK Current & Future Analysis for Human Microbiome by
Product Type - Probiotics, Prebiotics, Foods, Medical Foods,
Drugs and Other Product Types - Independent Analysis of Annual
Sales in US$ Million for the Years 2018 through 2027
Table 131: UK Historic Review for Human Microbiome by Product
Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and
Other Product Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2017
Table 132: UK 15-Year Perspective for Human Microbiome by
Product Type - Percentage Breakdown of Value Sales for
Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other
Product Types for the Years 2012, 2018 & 2027
REST OF EUROPE
Table 133: Rest of Europe Current & Future Analysis for Human
Microbiome by Disease Indication - Acute Diarrhea, Obesity,
Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and
Other Diseases - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027
Table 134: Rest of Europe Historic Review for Human Microbiome
by Disease Indication - Acute Diarrhea, Obesity, Diabetes,
Autoimmune Disorders, Cancer, Mental Disorders and Other
Diseases Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017
Table 135: Rest of Europe 15-Year Perspective for Human
Microbiome by Disease Indication - Percentage Breakdown of
Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune
*Please contact our Customer Support Center to get the complete Table of Contents*
Read the full report: https://www.reportlinker.com/p05956987/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001